Bi-specific antibodies (BsAb) recognize and bind two different antigens or epitopes simultaneously and block two different signaling pathways to exert their effects. Compared with monoclonal Ab (mAb), which recognizes a single antigen, BsAb has many advantages. First, BsAb can redirect specific immune effector cells to adjacent tumor cells to enhance tumor killing, and BsAb can also increase binding specificity through the interaction of two different cell surface antigens. In addition, BsAb is able to simultaneously block two different pathways that perform distinct or overlapping functions in pathogenesis compared to drugs with single antibodies in combination therapies.
The future of BsAb research continues to show a positive outlook, with much relevant research underway and many conferences taking place on this topic. This article takes a look at the exciting conferences that cannot be missed in the second half of 2022.
- The 13th World Multispecifics Summit
The 13th World Multispecifics Summit is the end-to-end meeting committed solely to advancing the development of bi- & multi-specific therapeutics. A wider range and deeper depth of cutting-edge technical topics will be presented at this summit, covering unique target discovery, mechanistic diversity and translational science as well as novel formats, product design and manufacturability challenges faced in the bispecific field.
This event is organized by Hanson Wade, and will be on September 20 -22, 2022, at Hilton Boston Logan Airport, One Hotel Drive, Boston, MA.
- The 5th Annual Bispecific Antibodies for Cancer Immunotherapy Conference
The 5th Annual Bispecific Antibodies for Cancer Immunotherapy Conference held by Cambridge Healthtech Institute will showcase advances in emerging targets, novel approaches to targeting, new constructs, and expanding the range of target antigens via multispecificity. The conference will also talk about strategies for improving the therapeutic index of T cell engagers, overcoming challenges such as agonism, and “tuning” of specificity and technologies for improving discovery stage selections.
This event will be on October 12-13, 2022, at Seaport Hotel Boston, One Seaport Lane, Boston, MA.
- The AntibodyEngineering & Therapeutics US
The Antibody Engineering & Therapeutics US will focus on the latest science and research on antibody engineering, design and selection diving into critical topics including immuno-oncology, cellular engagers, miniproteins, the Fc region, cancer therapy, novel bi-specifics/multispecifics and much more.
This event will be on December 4-8, 2022, at Marriott Marquis San Diego, CA.
“By bringing together experts in the industry to share the latest technologies and research results, these events may provide some new ideas and approaches for future BsAb research,” said a research scientist from Creative Biolabs who is going to attend the 13th World Multispecifics Summit, “we have been working on optimizing our bispecific antibody development service for years, and can’t wait to be a part of these events, meet more new people, and get inspired.”
BsAbs hold great promise for clinical applications with unique concepts not found in monoclonal antibodies, but there are significant challenges in translating these concepts into clinically applicable therapeutic approaches. With the advancement of numerous clinical studies and upstream and downstream technological advances, different effect mechanisms are gradually being validated, and BsAbs are expected to provide new development opportunities for novel drug design and development.
0
